CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,011 enrolled
Drug / intervention
nirmatrelvir, ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06291831
NCT06291831N/ACompleted

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HRU) Among COVID-19 Patients With or Without Nirmatrelvir/Ritonavir (PAXLOVID™) Treatment in the Kingdom of Bahrain.

Pfizer·observational·Posted Mar 4, 2024·Updated Aug 19, 2025

In Brief

An observational study evaluating nirmatrelvir, ritonavir and Controls for COVID-19. Completed, enrolled 3,011 participants across 1 site.

Detailed Summary

The purpose of this study is to collect information on the: * general information of a group of people such as their age, sex * clinical information of the patients such as any other illness before having COVID 19. * the number of COVID-19 patients who meet and follow the most up to date World Health Organization (WHO) recommendations for medication to treat COVID-19 (such as version 14, published 10Nov2023) compared to Kingdom of Bahrain national recommendations * adult COVID-19 patients' health care resource use and outcomes within the 28-day period In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment. This study will be conducted in the Kingdom of Bahrain. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment and those not treated with nirmatrelvir, ritonavir. This study will have about 3000 patients treated with Paxlovid™ therapy and 1000 were not. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers. The study will include patient information of those who: * had COVID-19 infection during the study period from 16 February 2022 to 30 November 2022. * are 18 years of age or older. This study will help to inform decision-making on use of Paxlovid at the national level.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesBahrain
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedMar 4, 2024
Enrollment StartMar 13, 2024
Primary CompletionMay 14, 2024
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.3 years ago

Interventions

nirmatrelvir, ritonavirdrug

Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)

Controlsother

Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)